Germline BRCA2 mutation in a patient with fallopian tube carcinoma: A case report

被引：45

作者：

Rose, PG

Shrigley, R

Wiesner, GL

机构：

[1] Univ Hosp Cleveland, Dept Reprod Biol, Div Gynecol Oncol, Cleveland, OH 44106 USA

[2] Univ Hosp Cleveland, Ctr Human Genet, Cleveland, OH 44106 USA

[3] Univ Hosp Cleveland, Dept Genet, Cleveland, OH 44106 USA

[4] Case Western Reserve Univ, Cleveland, OH 44106 USA

来源：

GYNECOLOGIC ONCOLOGY | 2000年 / 77卷 / 02期

关键词：

D O I：

10.1006/gyno.2000.5740

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives. Fallopian tube carcinoma is similar to ovarian and peritoneal carcinoma with respect to histology, response to chemotherapy, and prognosis. BRCA germline mutations have been commonly reported in ovarian and peritoneal carcinoma but rarely in other gynecologic cancers. Methods. A patient with fallopian tube carcinoma and a family history of ovarian carcinoma underwent genetic counseling and BRCA testing as did her daughter. Results. The patient and her daughter were found to have a germline BRCA2 mutation. Conclusion. Like a family history of ovarian or peritoneal carcinoma, the occurrence of fallopian tube cancer should alert the clinician to the possibility of an abnormality in the breast cancer susceptibility 1 or 2 genes. (C) 2000 Academic Press.

引用

页码：319 / 320

页数：2

共 13 条

[1] BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum [J].

Bandera, CA ;

Muto, MG ;

Schorge, JO ;

Berkowitz, RS ;

Rubin, SC ;

Mok, SC .

OBSTETRICS AND GYNECOLOGY, 1998, 92 (04) :596-600

[2]

Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310

[3]

Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO

[4]

2-Z

[5] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS [J].

FORD, D ;

EASTON, DF ;

BISHOP, DT ;

NAROD, SA ;

GOLDGAR, DE ;

HAITES, N ;

MILNER, B ;

ALLAN, L ;

PONDER, BAJ ;

PETO, J ;

SMITH, S ;

STRATTON, M ;

LENOIR, GM ;

FEUNTEUN, J ;

LYNCH, H ;

ARASON, A ;

BARKARDOTTIR, R ;

EGILSSON, V ;

BLACK, DM ;

KELSELL, D ;

SPURR, N ;

DEVILEE, P ;

CORNELISSE, CJ ;

VARSEN, H ;

BIRCH, JM ;

SKOLNICK, M ;

SANTIBANEZKOREF, MS ;

TEARE, D ;

STEEL, M ;

PORTER, D ;

COHEN, BB ;

CAROTHERS, A ;

SMYTH, E ;

WEBER, B ;

NEWBOLD, B ;

BOEHNKE, M ;

COLLINS, FS ;

CANNONALBRIGHT, LA ;

GOLDGAR, D .

LANCET, 1994, 343 (8899) :692-695

[6] Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility [J].

Offit, K ;

Biesecker, BB ;

Burt, RW ;

Clayton, EW ;

Garber, JE ;

Kahn, MJE .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1730-1736

[7] Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 [J].

Roa, BB ;

Boyd, AA ;

Volcik, K ;

Richards, CS .

NATURE GENETICS, 1996, 14 (02) :185-187

[8]

Schubert EK, 1997, AM J HUM GENET, V60, P1031

[9]

SEDLIS A, 1961, Obstet Gynecol Surv, V16, P209, DOI 10.1097/00006254-196104000-00022

[10] The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [J].

Struewing, JP ;

Hartge, P ;

Wacholder, S ;

Baker, SM ;

Berlin, M ;

McAdams, M ;

Timmerman, MM ;

Brody, LC ;

Tucker, MA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (20) :1401-1408

← 1 2 →